Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Obesity drugs

<< Previous

Bullboard Posts

Next >>

Comment by Qwerty54321on Feb 22, 2024 8:37pm

47 Views

Post# 35894756

RE:RE:RE:RE:Obesity drugs

If you were to take a pill of this drug it would get digested by the stomach.

Mannequin wrote:
We are told that there can never be a pill version, so maybe it's the sheer cost of manufacturing? However if you were to manufacturer at huge scale, does that allow you to reduce the costs while growing sales? And can you introduce a different low cost variant?

PWIB123 wrote: I don't know enough about how pharmacueticals manage pricing, and I cannot get my head wrapped around how they make EGRIFTA more affordable for the masses. Any thoughts there?

palinc2000 wrote:
From the transcripts of yesterday d CC

In fact, our total number of unique patients hit an all-time high at the end of calendar 2023, up 13% year-over-year for the month of December. Allow me for a moment now to remind people about the EGRIFTA SV's benefits and marketing position, given the noise about weight loss drugs and particularly GLP-1s, where recent clinical research has shown them to also induce muscle mass reduction.

As the only medication of its kind approved in the US and designed specifically for adults with HIV, EGRIFTA SV's unique mechanism of action decreases excess visceral abdominal fat while actually increasing lean body mass.

This is especially important people with HIV where muscle loss can be a serious issue. Furthermore, healthcare providers are increasingly recognizing that excess visceral abdominal fat is a medical condition that can lead to very serious health consequences if left untreated.

We welcome this shift in understanding and diagnosis that should support patient identification and market demand for EGRIFTA SV. Before we move on, I want to address the recent update concerning our sBLA for the F8 formulation of Tesamorelin and take a moment to review the facts and timelines.

palinc2000 wrote: https://seekingalpha.com/news/4070545-obesity-drugs-expand-us-gdp-goldman-sachs